Commentary|Videos|February 6, 2025
PICCOLO Data for Mirvetuximab Soravtansine in FRα+, Platinum-Sensitive Ovarian Cancer
Author(s)Floortje J. Backes, MD
Floortje J. Backes, MD, discusses data for mirvetuximab soravtansine in FRα-positive, platinum-sensitive ovarian cancer
Advertisement
Episodes in this series
Advertisement
Related to this article
The top 5 OncLive TV videos of the week cover insights in ovarian cancer, breast cancer, head and neck cancer, pancreatic cancer, and follicular lymphoma.
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Breakthrough Therapy Designation to JBS-003 for Radiation De-Escalation in HPV+ Oropharyngeal Cancer
2
Ivonescimab Meets OS End Point vs Pembrolizumab in First-Line PD-L1+ NSCLC
3
Etentamig Meets PFS, ORR Primary End Points in Triple-Class Exposed R/R Myeloma
4
A New Player in the Adjuvant Setting? GLP-1 Agonists and the Fight Against Breast Cancer Metastasis
5